ESMO 2021

Breast Cancer

Trastuzumab deruxtecan triples PFS

Presented By

Dr Javier Cortés, International Breast Cancer Center Barcelona, Spain

Trial

Phase 3, DESTINY-Breast03

Conference

ESMO 2021

19 November, 2021 09:51

Novel conjugate meets primary endpoint

Presented By

Dr Cristina Saura, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, TULIP

Conference

ESMO 2021

19 November, 2021 09:50

Longest survival benefit from first-line CDK4/6 inhibitor

Presented By

Prof. Gabriel Hortobagyi, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 3, MONALEESA-2

Conference

ESMO 2021

19 November, 2021 09:50

Meta-analysis shows 6-months adjuvant trastuzumab is optimal

Presented By

Prof. Helena Earl, Addenbrooke's Hospital, UK

Conference

ESMO 2021

19 November, 2021 09:50

BrighTNess data may change guidelines

Presented By

Prof. Sibylle Loibl, German Breast Group, Germany

Trial

Phase 3, BrighTNess

Conference

ESMO 2021

19 November, 2021 09:49

Double-positive results for triple-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, University of California, San Francisco, USA

Trial

Phase 3, KEYNOTE-355

Conference

ESMO 2021

19 November, 2021 09:48

Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy

Presented By

Prof. Valentina Guarneri, University of Padua, Italy

Conference

ESMO 2021

19 November, 2021 09:48

Postmenopausal breast cancer: extended letrozole reduces recurrence

Presented By

Prof. Lucia Del Mastro, University of Genoa, Italy

Trial

Phase 3

Conference

ESMO 2021

19 November, 2021 09:47

Asian women also benefit from palbociclib plus letrozole

Presented By

Prof. Binghe Xu, Peking Union Medical College, Beijing, China

Trial

Phase 3, PALOMA-4

Conference

ESMO 2021

19 November, 2021 09:47

No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better

Presented By

Prof. Miguel Martín Jiménez, Complutense University of Madrid, Spain

Trial

Phase 3, PEARL

Conference

ESMO 2021

19 November, 2021 09:45

Gastrointestinal Cancer

Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC

Presented By

Dr Pei-Rong Ding, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, CONVERT

Conference

ESMO 2021

19 November, 2021 09:43

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy

Trial

Phase 2, MAYA & AtezoTRIBE

Conference

ESMO 2021

19 November, 2021 09:42

Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC

Presented By

Dr Jared Weiss, University of North Carolina at Chapel Hill, NC, USA

Trial

Phase 1/2, KRYSTAL-1

Conference

ESMO 2021

19 November, 2021 09:42

Automated detection of microsatellite status on unstained samples in early colon cancer

Presented By

Dr Frederik Großerüschkamp, Ruhr-Universität Bochum, Germany

Conference

ESMO 2021

19 November, 2021 09:41

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate649

Conference

ESMO 2021

19 November, 2021 09:41

HIPEC in gastric cancer with peritoneal metastases

Presented By

Prof. Beate Rau, Charité University Hospital Berlin, Germany

Trial

Phase 3, GASTRIPEC I

Conference

ESMO 2021

19 November, 2021 09:41

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By

Dr Alexander Stein, University Cancer Center Hamburg, Germany

Trial

Phase 2, INTEGA

Conference

ESMO 2021

19 November, 2021 09:39

Lung Cancer

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, DESTINY-Lung01

Conference

ESMO 2021

19 November, 2021 09:36

Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM

Presented By

Prof. Solange Peters, Lausanne University Hospital, Switzerland

Trial

Phase 3, CheckMate743

Conference

ESMO 2021

19 November, 2021 09:36

Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, Impower010

Conference

ESMO 2021

19 November, 2021 09:35

Three-year OS follow-up from CASPIAN trial

Presented By

Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ESMO 2021

19 November, 2021 09:32

TCR clonality predicts pembrolizumab response in NSCLC

Presented By

Dr Afef Abed, Edith Cowan University, Australia

Conference

ESMO 2021

19 November, 2021 09:31

Melanoma

Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Presented By

Dr Jason Luke, UPMC Hillman Cancer Center, PA, USA

Trial

Phase 3, KEYNOTE-716

Conference

ESMO 2021

19 November, 2021 09:30

IFN-γ signature predicts response to immunotherapy

Presented By

Prof. Christian Blank, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, DONIMI

Conference

ESMO 2021

19 November, 2021 09:30

Updated results of SECOMBIT trial

Presented By

Prof. Paolo Ascierto, Istituto Nazionale Tumori "Fondazione Pascale", Italy

Trial

Phase 2, SECOMBIT

Conference

ESMO 2021

19 November, 2021 09:30

Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Presented By

Dr Helen Gogas, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, MASTERKEY-265

Conference

ESMO 2021

19 November, 2021 09:30

Durable intracranial responses with nivolumab/ipilimumab

Presented By

Dr Kim Margolin, City of Hope, CA, USA

Trial

Phase 2, CheckMate204

Conference

ESMO 2021

19 November, 2021 09:29

Genitourinary Cancer

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

19 November, 2021 09:27

TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

Presented By

Prof. Janet Brown, University of Sheffield, UK

Trial

Phase 2, STAR

Conference

ESMO 2021

19 November, 2021 09:26

Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Presented By

Dr Naveen Vasudev, St James University Hospital, UK

Trial

Phase 2, PRISM

Conference

ESMO 2021

19 November, 2021 09:26

Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer

Presented By

Dr Jeroen van Dorp, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, NABUCCO

Conference

ESMO 2021

19 November, 2021 09:26

Better survival with neoadjuvant dose-dense MVAC regimen in MIBC

Presented By

Dr Christian Pfister, Rouen University Hospital, France

Trial

Phase 3, VESPER

Conference

ESMO 2021

19 November, 2021 09:25

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By

Dr Eric Pujade-Lauraine, Université Paris Descartes, France

Trial

Phase 3, OReO/ENGOT Ov-38

Conference

ESMO 2021

19 November, 2021 09:24

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By

Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy

Trial

Phase 3, KEYNOTE-826

Conference

ESMO 2021

19 November, 2021 09:23

Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer

Presented By

Prof. David O’Malley, Ohio State University, USA

Trial

Phase 2, KEYNOTE-158

Conference

ESMO 2021

19 November, 2021 09:23

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By

Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, NRG-GY004

Conference

ESMO 2021

19 November, 2021 09:20

Haematological Cancer

Mutational analyses are predictive in malignant lymphomas

Presented By

Dr Ismael Fernández-Miranda, Institute of Sanitary Investigation Puerta de Hierro, Spain & Dr Shan-Shan Li, Hospital of Sun Yat-sen University, China

Conference

ESMO 2021

19 November, 2021 09:19

Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma

Presented By

Dr Liudmila Fedorova, Pavlov University, Russia

Conference

ESMO 2021

19 November, 2021 09:18

COVID-19

Adequate response to SARS-CoV-2 vaccine in cancer patients

Presented By

Dr Sjoukje Oosting, University Medical Center Groningen, the Netherlands & Dr Scott Shepherd, Royal Marsden NHS Foundation Trust, UK

Trial

VOICE & CAPTURE

Conference

ESMO 2021

19 November, 2021 09:15

Cancer patients more likely to die from COVID-19 when hospital admittance is required

Presented By

Dr Tom Drake, University of Edinburgh, UK

Conference

ESMO 2021

19 November, 2021 09:15

Third global survey of the ESMO Resilience Task Force

Presented By

Dr Jonathan Lim, Imperial College London, UK

Conference

ESMO 2021

19 November, 2021 09:15

High COVID-19 mortality in Swiss cancer patients

Presented By

Dr Markus Joerger, Cantonal Hospital St Gallen, Switzerland

Conference

ESMO 2021

19 November, 2021 09:14

Basic Science & Translational Research